INFORMATION DEPLOYED. SOLUTIONS ADVANCED. MISSIONS ACCOMPLISHED. Chemotherapy Order Management System (COMS) Stage 2 Enhancement Sprint Demonstration 3/7/2014 Audio: , Conference Code # * Please do not use telephone “hold” during meeting *

2 | CACI Information Solutions and Services | | CACI Proprietary Information Agenda  Welcome & Attendance  COMS Functionality Demonstration (Q & A throughout) Product Backlog − Proof of Concept: 53 Open, 11 Closed, 1 for Demonstration Today − Prototype: 8 Open, 4 Closed, 1 for Demonstration Today Defect Log − 22 Open, 13 Closed, 3 for Demonstration Today  Projected Activities for Next Sprint  Items for Discussion / Clarification  Wrap up & Adjournment

3 | CACI Information Solutions and Services | | CACI Proprietary Information COMS Functionality Demonstration  Product Backlog – Proof of Concept (53 Open, 11 Closed, 1 Today) Delivery Mechanism Documentation – to record device used  Product Backlog – Prototype (8 Open, 4 Closed, 1 Today) Template Printing Functionality  Defect Log (22 Open, 13 Closed, 3 Today) Remove Drug Confirmation for Therapy Medications Incomplete Display of Treatment Regimens & Summaries Misaligned Performance Status Pop-Up

4 | CACI Information Solutions and Services | | CACI Proprietary Information Projected Activities for Next Sprint  Medication Holds – for future order(s)  Remove Medications – for future order(s)  Display Dose Modification Rationale – for adjustments  Order Entry Management Link to Flow Sheet – as pop-up reference  Same Day Order Editing – prior to finalizing/dispensing  Documenting Attendance for Patient Discharge Instructions Methodology, Attendance, Determination of Comprehension, etc. Based on CPRS Template  Consent Duplicated – clarify statement verbiage

5 | CACI Information Solutions and Services | | CACI Proprietary Information Items for Discussion / Clarification  Neutropenia Risk Within Chemotherapy Template Order Source/Template Authoring Enable identification of neutropenia risk in accordance with VA guidelines, based on American Society of Clinical Oncology (ASCO) guidance and published literature so the provider can determine appropriateness of prophylaxis for neutropenia. Provide neutropenia risk references in a table and include an “unknown” option if the neutropenia risk is unavailable.  Emetogenic Level Medication Within Chemotherapy Template Order Source/Template Authoring Implement medication-based formula for emetogenic level

6 | CACI Information Solutions and Services | | CACI Proprietary Information Wrap Up And Adjournment 2014 Schedule January 3 January 24  February 14  March 7  March 28  April 18  May 9  May 30  June 20  July 11  August 1  August 22  September 12  October 3  October 24  November 14  December 5  Upcoming Demonstrations  Stakeholder Questions  Closing Comments